Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BASEL, SWITZERLAND AND LONDON AND NEW YORK, AUG. 11, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE.

ROIVANT REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2025, AND PROVIDES BUSINESS UPDATE

BASEL, SWITZERLAND AND LONDON AND NEW YORK, JULY 28, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED THAT IT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 8:00 A.M. ET ON MONDAY, AUGUST 11, 2025, TO REPORT ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2025, AND PROVIDE A BUSINESS UPDATE.

ROIVANT TO REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2025, AND PROVIDE BUSINESS UPDATE ON MONDAY, AUGUST 11, 2025

THREE PHASE 1 STUDIES SUPPORT ONCE-DAILY INHALED ADMINISTRATION OF MOSLICIGUAT WITH NO EVIDENCE OF SERIOUS SYSTEMIC SIDE EFFECTS

PULMOVANT ANNOUNCES PUBLICATION OF PHARMACOKINETICS AND LUNG DEPOSITION DATA FOR INHALED MOSLICIGUAT IN CLINICAL PHARMACOKINETICS

BASEL, SWITZERLAND AND LONDON AND NEW YORK, JUNE 09, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) AND PRIOVANT THERAPEUTICS TODAY ANNOUNCED THAT THEY WILL HOST A LIVE INVESTOR VIDEO CONFERENCE AT 1:00 PM ET ON TUESDAY, JUNE 17 ON BREPOCITINIB, THE UNMET MEDICAL NEED FOR PATIENTS WITH DERMATOMYOSITIS (DM) AND THE POTENTIAL ROLE BREPOCITINIB COULD PLAY IN IMPROVING THE LIVES OF PATIENTS WITH DM.

ROIVANT AND PRIOVANT TO HOST INVESTOR VIDEO CONFERENCE AT 1:00 PM ET ON TUESDAY, JUNE 17 ON BREPOCITINIB AND THE UNMET MEDICAL NEED IN DERMATOMYOSITIS

BASEL, SWITZERLAND AND LONDON AND NEW YORK, MAY 29, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2025, AND PROVIDED A BUSINESS UPDATE. BREPOCITINIB PROGRAM PROGRESSING WELL WITH RAPID ENROLLMENT IN NON-INFECTIOUS UVEITIS (NIU) PHASE 3 STUDY AND FIRST PATIENTS DOSED IN CUTANEOUS SARCOIDOSIS (CS) PROOF-OF-CONCEPT TRIAL, WITH READOUTS EXPECTED INTHE FIRST HALF OF CALENDAR YEAR 2027 AND SECOND HALF OF CALENDAR YEAR 2026, RESPECTIVELY BREPOCITINIB'S VALORPHASE 3 STUDY EVALUATING ITS USE IN PATIENTS WITH DERMATOMYOSITIS (DM) IS FULLY ENROLLED AND ON TRACK FOR TOPLINE DATA READOUT INTHE SECOND HALF OF CALENDAR YEAR 2025; ROIVANT AND PRIOVANT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 1:00 P.M.

ROIVANT REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2025, AND PROVIDES BUSINESS UPDATE

BASEL, SWITZERLAND AND LONDON AND NEW YORK, MAY 15, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED THAT IT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 8:00 A.M. ET ON THURSDAY, MAY 29, 2025, TO REPORT ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2025, AND PROVIDE A BUSINESS UPDATE.

ROIVANT TO REPORT FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2025 AND PROVIDE BUSINESS UPDATE ON THURSDAY, MAY 29, 2025

NEW YORK, APRIL 21, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT,INC.(NASDAQ:IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY ANNOUNCED NEXT PHASE OF GROWTH INCLUDING CHANGES TO ITS LEADERSHIP TEAM AND THE EXPANDED DEVELOPMENT OF IMVT-1402 INTO TWO NEW INDICATIONS, SJD AND CLE.

IMMUNOVANT ANNOUNCES NEXT PHASE OF GROWTH WITH ROIVANT INCLUDING CHANGES TO ITS LEADERSHIP TEAM AND ADDITIONAL INDICATIONS SJGREN'S DISEASE (SJD) AND CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) FOR IMVT-1402

NEW YORK, MARCH 19, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY REPORTED TOPLINE RESULTS FROM ITS PHASE 3 STUDY OF BATOCLIMAB IN MG AND INITIAL RESULTS FROM PERIOD 1 OF ITS PHASE 2B STUDY IN CIDP.

ROIVANT ANNOUNCES POSITIVE RESULTS FOR BATOCLIMAB MYASTHENIA GRAVIS (MG) AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) STUDIES

NEW YORK, MARCH 18, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT IT WILL HOST AN INVESTOR WEBCAST ON WEDNESDAY, MARCH 19TH AT 8:00 A.M. ET TO REVIEW RESULTS FROM ITS PHASE 3 STUDY OF BATOCLIMAB IN MG AND INITIAL RESULTS FROM ITS PHASE 2B STUDY IN CIDP.

ROIVANT TO HOST INVESTOR WEBCAST AT 8:00 AM ET ON WEDNESDAY, MARCH 19 TO REVIEW RESULTS FROM BATOCLIMAB MYASTHENIA GRAVIS (MG) AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PROGRAMS

BASEL, SWITZERLAND AND VANCOUVER, B.C. AND WARMINSTER, PA., MARCH 03, 2025 (GLOBE NEWSWIRE) -- GENEVANT SCIENCES, A LEADING NUCLEIC ACID DELIVERY COMPANY WITH WORLD-CLASS PLATFORMS AND A ROBUST LIPID NANOPARTICLE (LNP) PATENT PORTFOLIO (A SUBSIDIARY OF ROIVANT SCIENCES, LTD. (NASDAQ: ROIV)), AND ARBUTUS BIOPHARMA CORPORATION (NASDAQ: ABUS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON INFECTIOUS DISEASE, TODAY FILED FIVE INTERNATIONAL LAWSUITS SEEKING TO ENFORCE PATENTS PROTECTING THEIR INNOVATIVE LNP TECHNOLOGY AGAINST MODERNA, INC. AND CERTAIN AFFILIATES. TOGETHER, THE ENFORCEMENT ACTIONS TARGET ALLEGED INFRINGING ACTIVITIES IN 30 COUNTRIES.

GENEVANT SCIENCES AND ARBUTUS BIOPHARMA INITIATE INTERNATIONAL PATENT INFRINGEMENT ENFORCEMENT ACTIONS AGAINST MODERNA

BASEL, SWITZERLAND AND LONDON AND NEW YORK, FEB. 10, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY REPORTED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2024, AND PROVIDED A BUSINESS UPDATE. BREPOCITINIB TO BE DEVELOPED IN THIRD INDICATION, CUTANEOUS SARCOIDOSIS (CS), AN ORPHAN INDICATION WITH HIGH UNMET NEED; PHASE 2 STUDY INITIATION EXPECTED INSECOND QUARTER OF CALENDAR YEAR WITH TOPLINE DATA IN SECOND HALF OF CALENDAR YEAR 2026 IMVT-1402 DEVELOPMENT IS RAPIDLY PROGRESSING WITH SIX INVESTIGATIONAL NEW DRUG (IND) APPLICATIONS CLEARED AND PIVOTAL STUDIES IN GRAVES' DISEASE (GD) AND DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS (D2T RA) INITIATED BATOCLIMAB TOPLINE RESULTS FROM PIVOTAL TRIAL IN MYASTHENIA GRAVIS (MG) AND INITIAL RESULTS FROM PERIOD 1 OF TRIAL IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) EXPECTED BY MARCH 31, 2025 PROGRESS IN ONGOING LNP LITIGATION, WITH THE SUMMARY JUDGMENT PHASE IN THE MODERNA CASE TAKING PLACE ACROSS THE SECOND AND THIRD QUARTERS OF CALENDAR YEAR 2025 AND A JURY TRIAL SCHEDULED FOR SEPTEMBER 2025 ROIVANT REPORTED CONSOLIDATED CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES OF APPROXIMATELY $5.2 BILLION AT DECEMBER 31, 2024, NOT INCLUDING A ONE-TIME REGULATORY MILESTONE OF $75 MILLION RECEIVED IN JANUARY FOR THE APPROVAL OF VTAMA IN ATOPIC DERMATITIS AND $113 MILLION OF EXTERNAL CAPITAL RAISED IN IMMUNOVANT'S JANUARY PRIVATE PLACEMENT ROIVANT HAS BROADENED OUR CLINICAL PIPELINE WITH THE NEWLY ANNOUNCED TRIAL OF BREPOCITINIB IN CUTANEOUS SARCOIDOSIS.

Roivant Sciences Ltd.

ROIV

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Roivant Sciences Ltd.

ROIV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ROIV